News
Lilly raises full-year earnings forecasts on surging demand for weight-loss drug
Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, Zepbound, as it targets new markets and looks to grab more share from Novo Nordisk's Wegovy.
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Pharmaceutical Technology on MSN18h
Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly
Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.
Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage ...
While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...
Eli Lilly & Co.’s experimental pill helped patients shed roughly 11% of their body weight, about 25 pounds, in a late-stage ...
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company also released long-awaited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback